BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 32372673)

  • 1. Potential markers of disease behavior in acromegaly and gigantism.
    Hernández-Ramírez LC
    Expert Rev Endocrinol Metab; 2020 May; 15(3):171-183. PubMed ID: 32372673
    [No Abstract]   [Full Text] [Related]  

  • 2. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
    Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
    Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
    Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
    Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A legendary sumo wrestler with gigantism or acromegaly? The case of Ikezuki Geitazaemon (1827-1850).
    Takada K; Sasano M; Hayakawa S
    Med Hypotheses; 2020 Nov; 144():110174. PubMed ID: 33254497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary gigantism: Causes and clinical characteristics.
    Rostomyan L; Daly AF; Beckers A
    Ann Endocrinol (Paris); 2015 Dec; 76(6):643-9. PubMed ID: 26585365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of gigantism and acromegaly.
    Hannah-Shmouni F; Trivellin G; Stratakis CA
    Growth Horm IGF Res; 2016; 30-31():37-41. PubMed ID: 27657986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diagnosis in acromegaly and gigantism: From research to clinical practice.
    Ramírez-Rentería C; Hernández-Ramírez LC
    Best Pract Res Clin Endocrinol Metab; 2024 May; 38(3):101892. PubMed ID: 38521632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoacromegaly-A challenging entity in the endocrine clinic: A systematic review.
    Marques P; Sapinho I; Korbonits M
    Clin Endocrinol (Oxf); 2024 Jun; 100(6):542-557. PubMed ID: 38549284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acromegaly resolution after traumatic brain injury: a case report.
    Cob A
    J Med Case Rep; 2014 Sep; 8():290. PubMed ID: 25182385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acromegaly and it's cardiovascular implications].
    Cadena-Obando DA; Remba-Shapiro I; Abreu-Rosario CG; Mercado M
    Rev Med Inst Mex Seguro Soc; 2021 Feb; 59(1):73-80. PubMed ID: 33667046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.
    Cansu GB; Taşkıran B; Trivellin G; Faucz FR; Stratakis CA
    Hormones (Athens); 2016 Jul; 15(3):441-444. PubMed ID: 27838609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I.
    Miyazaki R; Yoshida T; Sakane N; Yasuda T; Umekawa T; Kondo M; Shimatsu A; Hizuka N; Sano T
    Intern Med; 1995 Mar; 34(3):183-7. PubMed ID: 7787324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Mosbah H; Brue T; Chanson P
    Ann Endocrinol (Paris); 2019 Sep; 80 Suppl 1():S10-S18. PubMed ID: 31606057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexisting diseases modifying each other’s presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism.
    Dragović T; Đuran Z; Jelić S; Marinković D; Kiković S; Kuzmić-Janković S; Hajduković Z
    Vojnosanit Pregl; 2016 Oct; 73(10):961-6. PubMed ID: 29328563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.